Evidence map›Paper›PMID 41745126›Full record

ArticleMicrobiology spectrum2026

Heteroresistance to amikacin in

Natália Ribeiro Crispim, Gustavo Dantas Nunes, Gabriela Guerrera Soares, Rebecca Elizabeth Shilling, Roumayne Lopes Ferreira, Leslie Camelo Campos, Olinda Soares Athaide Alcobaça, João Pedro Maia de Oliveira da Silva, Saulo Henrique Rodrigues, André Pitondo-Silva and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Natália Ribeiro Crispim *Departamento de Genética e Evolução, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil.ORCID 0009-0008-6560-9358
Gustavo Dantas Nunes *Departamento de Genética e Evolução, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil.
Gabriela Guerrera Soares *Departamento de Genética e Evolução, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil.
Rebecca Elizabeth Shilling *Departamento de Genética e Evolução, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil.
Roumayne Lopes FerreiraDepartamento de Genética e Evolução, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil.
Leslie Camelo CamposLaboratório Central de Saúde Pública do Tocantins, Palmas, Tocantins, Brazil.
Olinda Soares Athaide AlcobaçaDepartamento de Genética e Evolução, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil.
João Pedro Maia de Oliveira da SilvaDepartamento de Genética e Evolução, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil.
Saulo Henrique RodriguesDepartamento de Genética e Evolução, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil.
André Pitondo-SilvaProgramas de Pós-graduação em Odontologia, Biotecnologia e Tecnologia Ambiental, Universidade de Ribeirão Preto, Ribeirao Preto, Brazil.
Andrea Soares da Costa FuentesDepartamento de Genética e Evolução, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil.
Anderson Ferreira da CunhaDepartamento de Genética e Evolução, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil.
Robert J MitchellDepartment of Biological Sciences, Ulsan National Institute of Science and Technology, Ulsan, South Korea.ORCID 0000-0002-9608-5381
Maria-Cristina da Silva PrancheviciusDepartamento de Genética e Evolução, Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil.ORCID 0000-0002-0416-7401

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior CAPES fellowship Finance code 001Fundação de Amparo à Pesquisa do Estado de São Paulo FAPESP fellowship 2021/08423-4Fundação de Amparo à Pesquisa do Estado de São Paulo FAPESP fellowship 2022/12429-0Fundação de Amparo à Pesquisa do Estado de São Paulo FAPESP fellowship 2023/08917-2Fundação de Amparo à Pesquisa do Estado de São Paulo FAPESP fellowship 2023/14763-8Fundação de Amparo à Pesquisa do Estado de São Paulo FAPESP grant 2020/11964-4Fundação de Amparo à Pesquisa do Estado de São Paulo FAPESP grant 2022/16872-6Korea National Institute of Health Grant No. 2023ER210802
6 · The paper itself

Abstract

Heteroresistance is defined by the presence of subpopulations within a bacterial isolate that exhibit greater antibiotic resistance than the dominant population. In this study, we investigated amikacin heteroresistance in the opportunistic, nosocomial pathogen IMPORTANCE:

Indexed as

AmikacinAnti-Bacterial AgentsEnterobacter aerogenesKlebsiella InfectionsBacterial Proteinsbeta-LactamasesBrazilDrug Resistance, BacterialHumansIntensive Care UnitsMicrobial Sensitivity TestsAmikacinAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasescarbapenemaseamikacinheteroresistanceintensive care unitKlebsiella aerogenesresistance geneswhole-genome sequencing

Identifiers

PMID41745126
PMCPMC13055279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.